IRA, AI Regulation, and the Future with Joe Grogan
Jan 23, 2024
auto_awesome
Joe Grogan, senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics, discusses his experience during the early days of the COVID pandemic. He shares insights on the Inflation Reduction Act's impact on pharmaceutical R&D and the future of AI regulation.
Bipartisan collaboration and innovation in healthcare are crucial for effectively addressing future challenges.
A rational and balanced approach to AI regulation is needed to harness its potential benefits in the healthcare industry.
Deep dives
Joe Grogan's Experience during the Early Days of COVID Pandemic
Joe Grogan, Senior Fellow at Leonard D. Schaeffer Center for Health Policy and Economics, discusses his experience working in government during the early days of the COVID pandemic. Grogan shares his initial concerns about the outbreak and the need for quick organization and preparation. He highlights the challenges faced by the coronavirus task force, including the issues with cruise ship outbreaks, the need for personal protective equipment, and the economic impact of travel restrictions. Grogan emphasizes the importance of bipartisan collaboration and innovation in healthcare to effectively address future challenges.
Impact of Inflation Reduction Act on Drug Pricing
Grogan provides his perspective on the Inflation Reduction Act (IRA) and its impact on drug pricing. He criticizes the partisan nature of the legislation and expresses concern about the government setting price controls for innovative drugs. Grogan argues that price controls are inefficient and often lead to shortages. He suggests the need for bipartisan cooperation and innovation in payment systems to ensure access to affordable drugs while maintaining incentives for innovation and research.
Regulating AI in Healthcare
Grogan shares his thoughts on the policy and regulation of artificial intelligence (AI) in healthcare. He expresses skepticism towards the fear-mongering and calls for excessive regulation of AI. Grogan believes there is tremendous potential for AI to lower costs, improve outcomes, and drive innovation in healthcare. He advocates for a rational and balanced approach to AI regulation, highlighting the importance of small innovators and bipartisan collaboration in advancing AI technology and its benefits in the healthcare industry.
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
Together, they dive into Joe’s experience working in the early days of the Covid pandemic, how he thinks about the Inflation Reduction Act’s effect on pharmaceutical R&D, and the future of AI regulation.
Additional reading:
Check out Joe's latest op-ed here, his own podcast here, and his Twitter account here.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode